Some Hospitals Pay to Retain On-Call Specialists

BY JANE ANDERSON Contributing Writer

pecialists across the country are demanding payment for being on call to the emergency department, and many hospitals are acceding in an effort to keep full coverage.

But even though more than one-third of hospitals now pay their on-call specialists, experts in emergency medicine say the oncall specialist crisis isn't one that can be solved by money. "Money talks, but only to a point," said Dr. Todd B. Taylor, an emergency physician in Nashville, Tenn., and speaker of the American College of Emergency Physicians Council. "Money is not going to solve this problem because of the other issues involved. At some point, you bankrupt the system."

For example, Dr. Taylor said he calculated that paying all on-call specialists "the going rate" (\$1,000 a night and up) would cost hospitals in just the state of Arizona

PRECAUTIONS

\$176 million annually. "And that's assuming you could find people willing to do it at all. I've seen many specialists who say 'You can't pay me enough to do this.' " he said. " If you don't solve the liability issues surrounding being on call, at some point nothing else matters."

The American Hospital Association found in survey data from 1 year ago that 38% of hospitals paid "for at least some coverage," said Caroline Steinberg, AHA's vice president for trends analysis. "It seems

to be a growing trend," she commented. And, in a study released in January on-

line in the Annals of Emergency Medicine, researchers from Oregon Health & Science University (OHSU), Sutter Emergency Medical Associates, the University of Iowa, and the Office of Oregon Health Policy and Research reported that 43% of Oregon's 54 hospitals pay a stipend to at least one specialty, and 31% of hospitals guarantee pay for uninsured patients treated on call. Stipends ranged from \$300 per month to more than \$3,000 per night, with a median stipend of \$1,000 per night to take call.

The statewide survey, conducted in the summer of 2005, showed coverage shortages in most specialties, with the most acute shortages in orthopedics and neurosurgery. More than half of all hospitals expressed difficulty in maintaining specialists on call for three or more specialties.

Orthopedists, neurosurgeons, and trauma surgeons were the specialists most likely to receive stipends, as reported in the survey. But survey author K. John Mc-Connell, Ph.D., a researcher in emergency medicine at OHSU, noted that he also is beginning to hear about hand surgeons, obstetricians, otolaryngologists, and urologists asking to be paid to be on call.

Many specialists now have the opportunity to practice in a 9-to-5 setting, Dr. McConnell said, which makes them less willing to be on call. "There's no evil intent or bad guys-it's just everyone responding to changing dynamics," he said.

Dr. Taylor agreed that lifestyle issues play a role in the shortage of on-call specialists and in their increasing demands to be paid for on-call duty. But he said that organizational and liability issues each play a bigger role. Hospitals and physicians must learn to arrange services and payment so that a specialist can be on call for 24 hours and then off the next day without losing income or hurting his or her own practice, Dr. Taylor said, adding that specialists "are starting to learn some lessons that emergency medicine learned years ago."

The AHA has not taken a position on payment of specialists for being on call, but Ms. Steinberg said the group is sympathetic to physicians' problems. "We understand that physicians are being underpaid by Medicare and by private payers, and are facing huge professional liability," she said.

Otolaryngologist Eric Furst of Springfield, Va., said that he and his ENT colleagues recently approached Inova Fairfax Hospital in an attempt to negotiate payment for being on call. Dr. Furst said that Inova Fairfax, the only level I trauma center in northern Virginia, requires its physicians to take call, and for his section, it amounts to a week at a time two times a year. Several ENT specialists have left because of the demands, he said, which increases the on-call burden for those who remain. "Before you know it, it is a huge financial hit in those weeks in your own practice," he said.

After its 22 urologists threatened to stop responding to on-call care earlier this year, Inova Fairfax set up a fund to reimburse all 36 medical and surgical specialties that participate in emergency department on call for indigent care.

MIRENA® (levonorgestrel-releasing intrauterine system) PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST HIV INFECTION (AIDS) AND OTHER Sexually transmitted diseases

Rx only

Rx only INDICATIONS AND USAGE: MIRENA® is indicated for intrauterine contraception for up to 5 years. Thereafter, if continued contraception is desired, the system should be replaced. **RECOMMENDED PATIENT PROFILE: MIRENA®** is recommended for women who have had at least one child, are in a stable, mutually monogamous relationship, have no history of pelvic inflammatory disease, and have no history of ectopic pregnancy. or condition that would predispose to ectopic pregnancy. **CONTRAINDICATIONS: MIRENA®** insertion is contraindicated when one or more of the following conditions exist: 1. Pregnancy or suspicion of pregnancy. 2. Congenital or acquired uterine anomaly including fibroids if they distort the uterine cavity. 3. Acute pelvic inflammatory disease or a history of pelvic inflammatory disease unless there has been a subsequent intrauterine pregnancy. 4. Postparture modemetritis or infected adortion in the past 3 months. 5. Known or suspected uterine or cervical neoplasia or unresolved, abnormal Pap smear. 6. Genital bleeding of unknown etiology. 7. Untreated acute cervicils or vaginitis, including bacterial vaginosis or other lower genital tract intections until infection is controlled. 8. Acute liver disease or liver tumor (benign or malignant). 9. Woman or her partner has multiple sexual partners. 10. Conditions associated with increased susceptibility to infections with micro-organisms. Such conditions include, but are not limited to, leulemia, acquired immune deficiency syntome (AIDS), and I.V. drug abuse. 11. Genital actionnycosis (See WARNINGS) I.2. A previously inserted IUD that has not been removed. 13. Hypersensitivity to any component of this product. 14. Known or suspected carcinoma of the breast. 15. History of ectopic pregnancy: In large clinical trials of **MIRENA®**, half of all pregnancies detected during the studies were **WARNINGS: 1. Ectopic** Pregnancy: In large clinical trials of **MIRENA®**, half of all pregnancies.

that has not been removed. 13. Hypersensitivity to any component of this product. 14. Known or suspected carcinoma of the breast. 15. History of ectopic pregnancy or condition that would predispose to ectopic pregnancy. WARNINGS: 1. Ectopic Pregnancy: In arge clinical trials of MIRENA* and for all pregnancies detected during the studies were ectopic. The per-year incidence of ectopic pregnancy in the clinical trials was approximately 1 ectopic pregnancy per 1000 users per year. The rate of ectopic pregnancy in the clinical trials of MIRENA* is not recommended for use in women with MIRENA* extension of using any contraception. Clinical trials of MIRENA* extension of using any contraception. Clinical trials of MIRENA* extension of ectopic pregnancy. They should be taught to recognize and report to their physician promptly any symptoms of ectopic pregnancy. Women who choes MIRENA* is not eccommended for use in women with a history of ectopic pregnancy. They should be taught to recognize and report to their physician promptly any symptoms of ectopic pregnancy. Women who choes MIRENA* is solicated with complications leading to loss of ferritily. 2. Intraturetine Pregnancy: should be cargitate pregnancy. Women with a WIRENA* in place, and this the event of an intraterine pregnancy with MIRENA*, the following should be considered. a) Septic abortion. In patients becoming pregnant with an IUD in place, septic abortion – with septicemia, septic should be availed that failure to remove MIRENA* increases the risk of miscarriage, sepsis, premature labor and premature delivery. She should be followed closely and advised to report immediately any fluike symptoms. Fever, chills, carging, pain, bleeding, vagnial disclarge or leakage of fluid. Clony-term effects on the ortspring are unknown. Because of the symptoms, faver, chills, carging, pain, bleeding, vagniad leading appresize of MIRENA* in the development of the congenital anomalies is unknown. As of September 1999, 32 live births following exposure to MIRENA* in the deve

The presence of known or suspected PID or in women with a history of PID unless there has been a subsequent intrautenne pregnancy. Use of IUDs has been associated with an increased risk of PID. The highest risk of PID occurs shortly after insertion (usually within the first 20 days thereafter) (see Insertion Precautions). A decision to use MIRENA⁻ must include consideration of the risks of PID. a) Women at increased risk for PID: PID is often associated with a sexually transmitted disease, and MIRENA⁺ users: All women who choose MIRENA⁺ must be informed prior to insertion to have ever had PID are at increased risk for a recurrence or re-infection. b) PID warning to MIRENA⁺ users: All women who choose MIRENA⁺ must be informed prior to insertion about the possibility of PID and report to their physician promptly any symptoms of pelvic inflammatory disease. These symptoms include development of menstrual disorders (prolonged or heavy bleeding), unusual vaqinal discharge, abdominal or pelvic pain or tenderness, dyspareunia, chills, and fever. c) Asymptomatic PID: PID may be asymptomatic but still result in tubal damage and its sequelae. d) Treatment of PID: Following a diagnosis of PID, or suspected PID, bacteriologic specimens should be obtained and antibidic therapy should be initiated promptly. Removal of MIRENA⁺ after initiation of antibidic therapy is usually appropriate. Guidelines for PID reatment reavailable from the Center for Disease Control (CC), Altaria, Georgia, Adequate PID treatment requires the application of current standards of therapy prevailing at the time of occurrence of the infection with reference to prescription labeling. Actinomycosis has been associated with IUDs symptomatic carrier is controversial because actinomycels can be found normally in the genital trac cultures in healthy women without IUDs. False positive findings of actinomycosis on Pap smears can be a problem. When possible, cortin the asymptomatic carrier is controversial because actinomycels can be found normally pregnancy or abortion in the event of method failure. The findings of the analysis are shown in the following table: Annual Number of Birth-Related or Method-Related Deaths Associated with Control of Fertility per 100,000 Nonsterile Women, by

| reality control method According to Age | | | | | | |
|---|-------|-------|-------|-------|-------|-------|
| AGE GROUP | | | | | | |
| METHODS | 15-19 | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 |
| No Birth Control Method/Term | 4.7 | 5.4 | 4.8 | 6.3 | 11.7 | 20.6 |
| No Birth Control Method/AB | 2.1 | 2.0 | 1.6 | 1.9 | 2.8 | 5.3 |
| IUD | 0.2 | 0.3 | 0.2 | 0.1 | 0.3 | 0.6 |
| Periodic Abstinence | 1.4 | 1.3 | 0.7 | 1.0 | 1.0 | 1.9 |
| Withdrawal | 0.9 | 1.7 | 0.9 | 1.3 | 0.8 | 1.5 |
| Condom | 0.6 | 1.2 | 0.6 | 0.9 | 0.5 | 1.0 |
| Diaphragm/Cap | 0.6 | 1.1 | 0.6 | 0.9 | 1.6 | 3.1 |
| Sponge | 0.8 | 1.5 | 0.8 | 1.1 | 2.2 | 4.1 |
| Spermicides | 1.6 | 1.9 | 1.4 | 1.9 | 1.5 | 2.7 |
| Oral Contraceptives | 0.8 | 1.3 | 1.1 | 1.8 | 1.0 | 1.9 |
| Implants/Injectables | 0.2 | 0.6 | 0.5 | 0.8 | 0.5 | 0.6 |
| Tubal Sterilization | 1.3 | 1.2 | 1.1 | 1.1 | 1.2 | 1.3 |
| Vacastomu | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 |

Hardap S. et al., Preventing Pregnancy, protecting health: a new look at birth control choices in the US. The Alan Guttmacher Institute 1991: 1-129

PATIENTS SHOULD BE COUNSELED THAT THIS PRODUCT DOES NOT PROTECT AGAINST HIV INFECTION (AIDS) AND OTHER SEXUALLY TRANSMITTED DISEASES.

<section-header>

Mirena (levonorgestrel-releasing intrauterine system)

blod pressure; • severe arterial disease such as stroke or myocardial infarction. **4. Glucose Tolerance**: Lewnorgestrel may affect glucose tolerance, and the blood glucose concentration should be monitored in diabetic users of **MIRENA®**. **DRUG INTERACTIONS**: The effect of hormonal contraceptives may be impaired by drugs which induce liver enzymes. The influence of these drugs on the contraceptive efficacy of **MIRENA®** has not been studied. **CARCINOGENSIS**: Long-term studies in animals to assess the carcinogenic potential of levonorgester leadsing intraterine system have not been performed. See **'WARNINGS'** section. **PRECNANCY**: Pregnancy Category X. See **'WARNINGS'** section. **NURSING MOTHERS**: Levonorgestrel has been identified in small quantities in the breast milk of lactating women using **MIRENA®**. In a study of 14 breastfeeding women using a **MIRENA®** prototype during lactation, mean infant serum levels of levonorgestrel were approximately 7% of maternal serum levels. Hormonal contraceptives are not recommended as the contraceptive method of first choice admin glactation. **PEDIATING USE:** Stafty and efficacy of **MIRENA®**[®] has no been stabilished in women of repro-ductive age. Use of this product before menarche is not indicated. (See **RECOMMENDED PATIENT PROFILE) GERIATING**. **USE: MIRENA®**[®] has not been studied in women over age 65 and is not currently approved for use in this population. INFOR-MATION FOR THE PATIENT: See Patient Labeling. Patients should also be advised that the prescribing information is available to them at their request. It is recommended that potential users be tuly informed about the risks and benefits associated with the use of **MIRENA®**, with other forms of contraception, and with no contraception at all. **Return** to **tertility**: About 40% of women wishing to become pregnant conceived within 12 months after removal of **MIRENA®**. Advensite **ERACTIONS**: The most strokus adverse reactions associated with the use of **MIRENA®**. Advensite **ERACTIONS**: The most serious

STORAGE AND HANDLING: Store at 25°C (77°F); with excursions permitted between 15°-30°C (59-86°F) [See USI Controlled Room Temperature] DIRECTIONS FOR USE: NOTE: Health care providers are advised to become thoroughly familiar with the insertior instructions before attempting insertion of MIRENA[®].

(B) 6004703 9/04 Manufactured for

(BAJER) Bayer HealthCare Pharmaceuticals Bayer HealthCare Pharmaceuticals Inc Wayne, NJ 07470 Manufactured in Finland © 2007, Bayer HealthCare Pharmaceuticals Inc. All rights reserved

06-150-0009BH February 200